Hayden is an assistant editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2021, where she produces written and video content covering multiple disease states.
She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on LinkedIn.
Several ACA Preventive Services “Up for Grabs” Following Federal Ruling
The ruling does not completely get rid of all preventive services coverage under the Affordable Care Act; it only applies to updates or new recommendations made by the US Preventative Services Task Force since March 2010.
Dr Jeremy Wigginton: Health Care Happens All the Time; Employers Need to Engage Their Population
For employers, keeping members engaged with their health care is one of the key factors that leads to better outcomes, said Jeremy Wigginton, MD, vice president of health quality and innovation at Blue Cross and Blue Shield of Louisiana.
Auditory Differences Between Children With and Without HIV
Similar to findings among young adults, children with HIV in Tanzania were found to have lower distortion product otoacoustic emissions (DPOAEs) and auditory brainstem responses (ABR) wave V amplitudes, compared with children without HIV.
How Real-Time Benefit Check Can Improve Prescriber Decision-Making and Treatment Uptake
Michael Burger, senior consultant at Point-of-Care Partners, explains that real-time benefit check lets physicians know how much a drug will cost the patient at the time they're writing the prescription, allowing them to give the patient a treatment they know they can afford.
What Are Some Health Plan Best Practices Surrounding Oncology Therapy Coverage?
In this AMCP Market Insights session, panelists discussed best practices and challenges when it comes to prescribing antibody drug conjugates, from the payer, provider, and patient perspectives, based on survey findings.
Jeffrey Casberg on Breakthrough Ophthalmic Drugs That Payers, Pharmacists Should Pay Attention to
Among these treatments is an aflibercept product with improved dosing for the patient that is coming up for approval in a few months, explained Jeffrey Casberg, senior director of pharmacy at IPD Analytics.
Dr Kevan Herold on Living With T1D: “There's Nothing You Do Without Thinking About It”
It's harder for younger children to deal with the complexities of managing type 1 diabetes (T1D), so a delayed diagnosis even by a few years is a big deal, said Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine.
AMCP 2023 Will Cover Biosimilars, Inflation Reduction Act, and Much More, Says Kimberly Westrich
Kimberly Westrich, director of value and access strategy at AmerisourceBergen, previews AMCP 2023 and her preconference session about incorporating value framework assessments into coverage and reimbursement decision-making.
Limiting Teplizumab Coverage to First-Degree Relatives Is a Mistake, Says Dr Kevan Herold
Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine, talks about some insurers' requirement for patients to have a first-degree relative with type 1 diabetes to qualify for coverage of teplizumab.